These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 4542084)

  • 1. Microscopic and ultrastructural changes of hormone-dependent rat mammary cancer treated with "anti-hormones".
    Pape C; Ahrens J; Schulz KD
    Acta Endocrinol Suppl (Copenh); 1973; 173():151. PubMed ID: 4542084
    [No Abstract]   [Full Text] [Related]  

  • 2. [Proceedings: Comparative animal experiments on the effectivity of various endocrine therapeutic methods in hormone dependent breast carcinoma].
    Schulz KD; Ahrens J
    Arch Gynakol; 1973 Sep; 214(1):296-7. PubMed ID: 4801462
    [No Abstract]   [Full Text] [Related]  

  • 3. [Proceedings: Morphological studies of hormone-depending mammary carcinoma of the rat following irradiation and cytostatic or endocrine therapy].
    Pape C; Ahrens J; Schulz KD
    Arch Gynakol; 1975 Nov; 219(1-4):174. PubMed ID: 1243276
    [No Abstract]   [Full Text] [Related]  

  • 4. Influence of ergot alkaloids on pituitary prolactin and prolactin-dependent processes.
    Floss HG; Cassady JM; Robbers JE
    J Pharm Sci; 1973 May; 62(5):699-715. PubMed ID: 4574586
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of ergocornine on transplanted mammary tumor growth and pituitary prolactin level in BALB/c mice.
    Singh DV; Meites J; Halmi L; Kortright KH; Brennan MJ
    J Natl Cancer Inst; 1972 Jun; 48(6):1727-31. PubMed ID: 5056256
    [No Abstract]   [Full Text] [Related]  

  • 6. Regression of spontaneous mammary tumors in rats by ergot drugs.
    Quadri SK; Meites J
    Proc Soc Exp Biol Med; 1971 Dec; 138(3):999-1001. PubMed ID: 5131642
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative effects of hypophysectomy, ergocornine and ergocornine-reserpine treatments on rat mammary carcinoma.
    Welsch CW; Iturri G; Meites J
    Int J Cancer; 1973 Jul; 12(1):206-12. PubMed ID: 4790704
    [No Abstract]   [Full Text] [Related]  

  • 8. The inhibition of hormone-dependent rat mammary cancer by clomiphene isomers.
    Wüstenberg B; Schulz KD
    Acta Endocrinol Suppl (Copenh); 1973; 173():66. PubMed ID: 4542141
    [No Abstract]   [Full Text] [Related]  

  • 9. Host immune potentiation of drug responses to a murine mammary adenocarcinoma.
    Radov LA; Haskill JS; Korn JH
    Int J Cancer; 1976 Jun; 17(6):773-9. PubMed ID: 947856
    [No Abstract]   [Full Text] [Related]  

  • 10. Nitrous oxide and the bone-marrow.
    Marinković D
    Lancet; 1978 Nov; 2(8097):998-9. PubMed ID: 82027
    [No Abstract]   [Full Text] [Related]  

  • 11. [Experimental chemotherapy of mammary neoplasms. A review].
    Schönenberger H; Kranzfelder G; Hoffmann E; Egginger G; Schmitt H; Taneja AK
    Pharmazie; 1976; 31(9):590-7. PubMed ID: 798208
    [No Abstract]   [Full Text] [Related]  

  • 12. Suppression of mammary hyperplastic nodule formation and pituitary prolactin secretion in mice induced by ergocornine or 2-bromo-a-ergocryptine.
    Yanai R; Nagasawa H
    J Natl Cancer Inst; 1970 Dec; 45(6):1105-12. PubMed ID: 5530649
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of ergocornine and ergocryptine on growth of 7,12-dimethylbenzanthracene-induced mammary tumors in rats.
    Cassell EE; Meites J; Welsch CW
    Cancer Res; 1971 Jul; 31(7):1051-3. PubMed ID: 5560385
    [No Abstract]   [Full Text] [Related]  

  • 14. Transplantable mouse mammary adenocarcinoma 16/c as a model in experimental cancer therapy. III. Sensitivity to antitumor drugs.
    Rak J; Kuśnierczyk H; Strzadała L; Kłosiewicz S; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):389-97. PubMed ID: 2639635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of DMBA-induced mammary carcinogenesis in the rat by 2-br- -ergocryptine (CB 154), an inhibitor of prolactin secretion, and by nafoxidine (U-11, 100 A), an estrogen antagonist.
    Heuson JC; Waelbroeck C; Legros N; Gallez G; Robyn C; L'Hermite M
    Gynecol Invest; 1971; 2(1):130-7. PubMed ID: 5170652
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined endocrine therapy and chemotherapy of mouse mammary tumors.
    Sluyser M; de Goeij CC; Evers SG
    Eur J Cancer (1965); 1981 Feb; 17(2):155-9. PubMed ID: 7262152
    [No Abstract]   [Full Text] [Related]  

  • 17. Prophylaxis of spontaneously developing mammary carcinoma in C3H-HeJ female mice by suppression of prolactin.
    Welsch CW; Gribler C
    Cancer Res; 1973 Nov; 33(11):2939-46. PubMed ID: 4795906
    [No Abstract]   [Full Text] [Related]  

  • 18. [Changes in the content and composition of gangliosides of tumors as affected by chemotherapeutic agents].
    Kozlov AM; Novikov AM; Bassalyk LS; Sof'ina ZP
    Eksp Onkol; 1984; 6(5):62-6. PubMed ID: 6510346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplantable mouse 16/c mammary adenocarcinoma as a model in experimental cancer therapy. II. Modification of tumor-host interactions by therapeutic procedures.
    Rak J; Strzadała L; Kuśnierczyk H; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):379-88. PubMed ID: 2639634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Proceedings: Biochemical studies on cis-clomiphene action mechanism in estrogen dependent breast carcinoma of the rat].
    Wüstenberg B; Schulz KD
    Arch Gynakol; 1973 Sep; 214(1):295-6. PubMed ID: 4801461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.